ClinicalTrials.gov
ClinicalTrials.gov Menu

Greater Occipital Nerve Block Versus Metoclopramide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03269435
Recruitment Status : Recruiting
First Posted : August 31, 2017
Last Update Posted : December 12, 2017
Sponsor:
Information provided by (Responsible Party):
Benjamin Friedman, Montefiore Medical Center

Brief Summary:
We are comparing a type of nerve block called greater occipital nerve block versus standard therapy among patients who present to an emergency department for acute migraine. This is a randomized, double-blind, double dummy study. The greater occipital nerve block will be performed bilaterally with bupivacaine 0.5%. Standard therapy is metoclopramide 10mg IV.

Condition or disease Intervention/treatment Phase
Migraine Procedure: Greater occipital nerve block with bupivacaine Drug: Metoclopramide Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 170 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double dummy design with IV placebo and placebo nerve block
Primary Purpose: Treatment
Official Title: A Randomized Trial of Greater Occipital Nerve Block With Bupivacaine Versus Intravenous Metoclopramide for Acute Migraine
Actual Study Start Date : November 1, 2017
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Migraine
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Greater Occipital Nerve Block

Bilateral greater occipital nerve block with bupivacaine 0.5%

+ Normal saline IV

Procedure: Greater occipital nerve block with bupivacaine
This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally
Active Comparator: Metoclopramide

Metoclopramide 10mg IV

+ Bilateral greater occipital nerve block with normal saline

Drug: Metoclopramide
Metoclopramide 10mg IV will be administered over 15 minutes



Primary Outcome Measures :
  1. Sustained headache relief [ Time Frame: 48 hours ]
    Headache level = mild or none. Achieved in emergency department and maintained for 48 hours without rescue medication


Secondary Outcome Measures :
  1. Sustained headache freedom [ Time Frame: 48 hours ]
    Headache = none, achieved in emergency department and maintained for 48 hours

  2. ED dwell time [ Time Frame: 48 hours ]
    Length of stay in ED: randomization to discharge

  3. Improvement in 0-10 pain score [ Time Frame: one hour ]
    Pain score assessed at baseline and one hour



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Gender Eligibility Description:   self-described
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Eligible patients are adults who present with an acute moderate or severe headache meeting migraine headache criteria, as defined by the International Classification of Headache Disorders-3β (1.1, migraine without aura). Patients who meet criteria for Probable Migraine without Aura (1.5.1) will also be included, provided they have had at least one similar attack previously.

Exclusion Criteria:

Patients will be excluded if informed consent cannot be obtained, if there is concern for a secondary cause of headache, if the maximum documented temperature is greater than 100.3 degrees, for a new objective neurologic abnormality, skull defect, suspected infection overlying injection site, known bleeding disorder, ongoing use of anti-platelet agents including P2Y12 platelet inhibitors (clopidogrel, prasugrel, ticagrelor), heparins, warfarin, or 10a inhibitors (rivaroxaban, apixaban, edoxaban, fondaparinux), prior treatment with a greater occipital nerve block, allergy to the investigational medications, pheochromocytoma, seizure disorder, Parkinson's disease, use of MAO inhibitors, and use of anti-rejection transplant medications.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03269435


Locations
United States, New York
Montefiore Medical Center Recruiting
Bronx, New York, United States, 10467
Contact: Benjamin W Friedman, MD, MS    718-920-6626    befriedm@montefiore.org   
Sponsors and Collaborators
Montefiore Medical Center

Responsible Party: Benjamin Friedman, Professor, Montefiore Medical Center
ClinicalTrials.gov Identifier: NCT03269435     History of Changes
Other Study ID Numbers: 2017-8249
First Posted: August 31, 2017    Key Record Dates
Last Update Posted: December 12, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Bupivacaine
Metoclopramide
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Antiemetics
Autonomic Agents
Gastrointestinal Agents
Dopamine D2 Receptor Antagonists
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action